Lung Cancer Clinical Trials & Research at St. Joseph Health Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

St. Joseph Health Medical Group is currently enrolling patients for the following lung cancer clinical trials:

A Novel Tumor DNA Damaging Drug, MSC2490484A, Given with Etoposide and Cisplatin Chemotherapy for Small Cell Lung Cancer Clinical Trial

  • ON HOLD
  • Extensive disease small cell lung cancer.
  • 1st line of treatment.
  • At least one measurable target lesion.
  • Patients enrolled in the Phase 1b study will receive treatment with MSC2490484A + etoposide & cisplatin.
  • Patients enrolled in the Phase II study will receive MSC2490484A or placebo + etoposide & cisplatin in a 2:1 ratio.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Tracy Foster, at (707) 521-3830 or at Tracy.Foster@stjoe.org.

A Novel CDK4/6 Inhibitor for Untreated Extensive-Stage on Small Cell Lung Cancer (SCLC)

  • Extensive-stage disease.
  • 1st line.
  • At least one measurable target lesion.
  • Patients will receive treatment with carboplatin + etopside + atezolizumab with or without trilaciclib.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Tracy Foster, at (707) 521-3830 or at Tracy.Foster@stjoe.org.

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study name: TAHOE.
  • Advanced or Stage IV SCLC.
  • Patients will receive treatment with rovalpituzuamb tesirine or topotecan (2:1 ratio).
  • Patients must have progressed on their first treatment, which must have been platinum based.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Sabine Ucik, at (707) 521-3830 or at Sabine.Ucik@stjoe.org.

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study name: MERU.
  • Extensive tumor burdern due to small cell lung cancer (SCLC).
  • Patients will receive treatment with rovalpituzuamb tesirine or a placebo (1:1 ratio).
  • Patients must have had a favorable outcome after at least 4 cycles of first-line platinum based chemotherapy.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Sabine Ucik, at (707) 521-3830 or at Sabine.Ucik@stjoe.org.

3rd generation TKI for EGFR+ Non-small Cell Lung Cancer (NSCLC) After Removal of Tumor Clinical Trial

  • Study name: ADAURA.
  • Stage IB-IIIA EGFR+ NSCLC.
  • Patients will receive treatment with AZD9291 (Tagrisso: 3rd generation TKI) or a placebo (1:1 ratio).
  • Patients must have completed surgery (tumor resection) prior to enrollment.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Tracy Foster, at (707) 521-3836 or at Tracy.Foster@stjoe.org.

Immunotherapy and Anti-hyaluronan Factor for Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC) Clinical Trial

  • Locally advanced or Stage IV (metastatic).
  • All patients receive treatment.
  • Patients must have failed at least one previous platinum-based chemotherapy prior to enrolling.
  • Patients need to be HA-high.
  • All patients are given pembrolizumab + PEGPH20.
  • More information about the study can be found at: www.halo101.com
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Tracy Foster, at (707) 521-3836 or at Tracy.Foster@stjoe.org.

Chemotherapy With or Without Anti-ErbB3 Antibody as 2nd, 3rd, or 4th Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

  • Study name: SHERLOC.
  • Stage IIIB-IV EGFR-negative.
  • Heregulin positive.
  • Patients must have undergone one or two, or three prior lines of treatment.
  • Patients receive treatment with chemotherapy, with or without MM-121, an anti-ErbB3 antibody (2:1 ratio).
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Sabine Ucik, at (707) 521-3830 or at Sabine.Ucik@stjoe.org.

MET Inhibitor for Small Cell Lung Canncer (SCLC) with MET Genetic Alteration Just in Time Clinical Trial

  • Stage IIIB-IV.
  • Genetic alteration activating MET in tumor tissue and/or ctDNA (ctDNA=blood draw looking for mutations).
  • Receipt of at least one prior treatment regimen in the advanced disease setting.
  • All patients receive treatment with MGCD265, an oral MET inhibitor.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Kimberly Young, at (707) 521-3814 or Kimberly.Young@stjoe.org.

MET Inhibitor for 2nd or 3rd Line Treatment for Non-Small Cell Lung Cancer (NSCLC) with MET Genetic Alteration Just in Time Clinical Trial

  • Stage IIIB-IV.
  • cMET amplification/mutation.
  • Received 1-2 prior lines of treatment.
  • All patients receive treatment with Capmatinib (INC280), an oral cMET inhibitor.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Kimberly Young, at (707) 521-3814 or Kimberly.Young@stjoe.org.

A Tissue Acquisition Study for Patients with Primary Diagnosis of Non-small Cell Lung Cancer (NSCLC)

  • There is no treatment involved with this study.
  • Receiving treatment with an anit-PD-(L)1 therapy, or already initiated treatment with anit-PD-(L)1 therapy.
  • Willing to provide archived tumor specimen or willing to undergo a biopsy procedure for the purpose of obtaining tumor tissue and/or tumor cells.
  • Able to provide periodic blood samples.
  • Main study doctor (Principal Investigator): Ian Anderson, MD.
  • For more information, please contact the lead coordinator, Kayla Denbeste, at (707) 521-3808 or Kayla.Denbeste@stjoe.org.

Our Locations